Danaher Co. (NYSE:DHR) Shares Sold by Griffin Asset Management Inc.

Griffin Asset Management Inc. trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 0.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,588 shares of the conglomerate’s stock after selling 89 shares during the quarter. Danaher accounts for about 1.4% of Griffin Asset Management Inc.’s portfolio, making the stock its 19th largest position. Griffin Asset Management Inc.’s holdings in Danaher were worth $11,612,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DHR. Wedge Capital Management L L P NC increased its holdings in shares of Danaher by 3.2% during the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 38 shares in the last quarter. Meridian Financial Partners LLC lifted its holdings in shares of Danaher by 4.4% during the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after purchasing an additional 40 shares during the period. Kovack Advisors Inc. raised its position in Danaher by 3.4% during the 3rd quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate’s stock worth $346,000 after buying an additional 41 shares during the last quarter. Well Done LLC grew its position in Danaher by 1.2% during the 3rd quarter. Well Done LLC now owns 3,551 shares of the conglomerate’s stock worth $987,000 after purchasing an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC lifted its holdings in shares of Danaher by 0.9% in the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate’s stock valued at $1,257,000 after buying an additional 42 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Danaher stock opened at $250.51 on Tuesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The business has a 50 day simple moving average of $235.33 and a 200-day simple moving average of $253.62. Danaher Co. has a 12 month low of $225.42 and a 12 month high of $281.70. The stock has a market capitalization of $180.94 billion, a PE ratio of 47.81, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is currently 20.61%.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on DHR. Barclays decreased their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 23rd. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Stephens restated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Finally, KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.